|
1.Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94:646-50. 2.Sinaki M. Postural changes in osteoporosis: musculoskeletal consequences non-pharmacological management of osteoporosis: Springer, Cham, 2017:207-17. 3.Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22:465-75. 4.Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393:364-76. 5.Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int. 2007;18(6):711-9. 6.Imaz I, Zegarra P, González-Enríquez J, et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2010;21:1943-51. 7.Adler RA, El-Hajj Fuleihan G, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31:16-35. 8.Ross S, Samuels E, Gairy K, et al. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health. 2011;14:571-81. 9.Hiligsmann M, Gathon HJ, Bruyere O, et al. Cost- effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health. 2010;13:394-401. 10.Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence:terminology and definitions. Value Health. 2008;11:44-7. 11.Hubbard T, Paradis R. Real world evidence: executive summary a new era for health care innovation. Netw Excell Heal Innov. 2015:1-19. 12.Fatoye F, Smith P, Gebrye T, et al. Real-world persistence and adherence with oral bisphosphonates for osteoporosis:a systematic review. BMJ Open. 2019;9(4):e027049. 13.Cheng TT, Yu SF, Hsu CY, et al. Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines. Clin Ther. 2013;35:1005-15. 14.Lin TC, Yang CY, Yang YH, et al. Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan. Clin Pharmacol Ther. 2011;90:109-16. 15.Soong YK, Tsai KS, Huang HY, et al. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Osteoporos Int. 2013;24:511-21. 16.Koller G, Goetz V, Vandermeer B, et al. Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporos Int. 2020; 31(11):2093-102. 17.Chan DC, Chang CHC, Lim LC et al. Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database. Osteoporos Int. 2016;27:2855-65. 18.Diab DL, Watts NB. Denosumab in osteoporosis. Expert Opin Drug Saf. 2014;13(2):247-53. 19.WHO. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129. 20.Wright NC, Looker AC, Saag KG, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29 (11):2520-26. 21.Hernlund E, Svedbom A, Ivergård M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8(1):136. 22.Lin YC, Pan WH. Bone mineral density in adults in Taiwan: results of the Nutrition and Health Survey in Taiwan 2005-2008 (NAHSIT 2005-2008). Asia Pac J Clin Nutr. 2011;20(2):283-91. 23.Pouresmaeili F, Kamalidehghan B, Kamarehei M, et al. A comprehensive overview on osteoporosis and its risk factors. Ther Clin Risk Manag. 2018;14:2029-49. 24.Stone KL, Seeley DG, Lui LY, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures. J Bone Miner Res. 2003;18(11):1947-54. 25.Kanis JA, Cooper C, Rizzoli R, et al; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3-44. 26.Chen JS, Sambrook PN. Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol. 2011;8(2):81-91. 27.Li SS, He SH, Xie PY, et al. Recent progresses in the treatment of osteoporosis. Front Pharmacol. 2021;12:717065. 28.Barrionuevo P, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab. 2019;104(5):1623-30. 29.Morley J, Moayyeri A, Ali L, et al. Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink. Osteoporos Int. 2020;31(3):533-45. 30.Chen YJ, Kung PT, Chou WY, et al. Alendronate medication possession ratio and the risk of second hip fracture: an 11-year population-based cohort study in Taiwan. Osteoporos Int. 2020;31(8):1555-63. 31.Hsu CL, Chen HM, Chen HJ, et al. A national study on long-term osteoporosis therapy and risk of recurrent fractures in patients with hip fracture. Arch Gerontol Geriatr. 2020;88:104021. 32.Yu SF, Cheng JS, Chen YC, et al. Adherence to anti-osteoporosis medication associated with lower mortality following hip fracture in older adults: a nationwide propensity score-matched cohort study. BMC Geriatr.2019;19(1):290. 33.Yeam CT, Chia S, Tan HCC, et al. A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos Int. 2018;29(12):2623-37. 34.Burkhart PV, Sabate E. Adherence to long-term therapies: evidence for action. J Nurs Scholarsh. 2003;35(3):207. 35.Cheen MH, Kong MC, Zhang RF, et al. Adherence to osteoporosis medications amongst Singaporean patients. Osteoporos Int. 2012;23(3):1053-60. 36.Richards JS, Cannon GW, Hayden CL, et al. Adherence with bisphosphonate therapy in US veterans with rheumatoid arthritis. Arthritis Care Res. 2012;64(12):1864-70. 37.Tandon VR, Sharma S, Mahajan S, et al. First Indian prospective Randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates. J Midlife Health. 2014;5(1):29-33. 38.Tasci I, Cintosun U, Safer U, et al. Assessment of geriatric predictors of adherence to zoledronic acid treatment for osteoporosis: a prospective follow-up study. Acta Clin Belg. 2018;73(4):237-43. 39.Hall SF, Edmonds SW, Lou Y, et al. Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy. J Am Pharm Assoc. 2017;57(4): 503-9. 40.Gomes DC, Costa-Paiva L, Farhat FC, et al. Ability to follow anti-reabsorptive drug treatment in postmenopausal women with reduced bone mass. Menopause. 2011;18(5):531-6. 41.Kishimoto H, Maehara M. Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA. Arch Osteoporos. 2015;10:231. 42.Lindsay BR, Olufade T, Bauer J, et al. Patient-reported barriers to osteoporosis therapy. Arch Osteoporos. 2016;11(1):19. 43.Chiu CK, Kuo MC, Yu SF, et al. Adherence to osteoporosis regimens among men and analysis of risk factors of poor compliance: a 2-year analytical review. BMC Musculoskelet Disord. 2013;14:276. 44.Foster SA, Foley KA, Meadows ES, et al. Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance. Osteoporos Int. 2011;22(2):551-7. 45.Wade SW, Satram-Hoang S, Stolshek BS. Long-term persistence and switching patterns among women using osteoporosis therapies: 24- and 36-month results from POSSIBLE US™. Osteoporos Int. 2014;25(9):2279-90. 46.Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. 47.Kobayashi K, Ando K, Machino M, et al. Persistence of denosumab therapy among patients with osteoporosis. Asian Spine J. 2020;14(4):453-8. 48.Briot K, Schott AM, Sanchez JP, et al. High persistence over two years with denosumab among postmenopausal women with osteoporosis in France: A prospective cohort study. Bone. 2021;146:115890. 49.Hadji P, Papaioannou N, Gielen E, et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int. 2015;26(10): 2479-89. 50.Yu SF, Chou CL, Lai HM, et al. Adherence to anti-osteoporotic regimens in a Southern Taiwanese population treated according to guidelines: a hospital-based study. Int J Rheum Dis. 2012;15(3):297-305. 51.Yu SF, Yang TS, Chiu WC, et al. Non-adherence to anti-osteoporotic medications in Taiwan: physician specialty makes a difference. J Bone Miner Metab. 2013;31(3):351-9. 52.Siris ES, Fan CS, Yang X, et al. Association between gastrointestinal events and compliance with osteoporosis therapy. Bone Rep. 2015;4:5-10. 53.Modi A, Sajjan S, Michael Lewiecki E, et al. Relationship between gastrointestinal events and compliance with osteoporosis therapy: an administrative claims analysis of the US managed care population. Clin Ther. 2016;38(5):1074-80. 54.Modi A, Siris S, Yang X, et al. Association between gastrointestinal events and persistence with osteoporosis therapy: analysis of administrative claims of a U.S. managed care population. J Manag Care Spec Pharm. 2015;21(6):499-506. 55.Jacob L, Dreher M, Kostev K, et al. Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture. Osteoporos Int. 2016;27(3):963-9. 56.Orimo H, Sato M, Kimura S, et al. Understanding the factors associated with initiation and adherence of osteoporosis medication in Japan: an analysis of patient perceptions. Osteoporos Sarcopenia. 2017;3(4):174-84. 57.Wang CY, Fu SH, Yang RS, et al. Timing of anti-osteoporosis medications initiation after a hip fracture affects the risk of subsequent fracture: a nationwide cohort study. Bone. 2020;138:115452. 58.Anastasilakis AD, Polyzos SA, Makras P, et al. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. 2017;32(6):1291-6. 59.Anastasilakis AD, Yavropoulou MP, Makras P, et al. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur J Endocrinol. 2017;176(6):677-83. 60.Zanchetta MB, Boailchuk J, Massari F, et al. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study. Osteoporos Int. 2018;29(1):41-7. 61.Martin J, Viprey M, Castagne B, et al. Interventions to improve osteoporosis care: a systematic review and meta-analysis. Osteoporos Int. 2020;31(3):429-46. 62.Wu CH, Tu ST, Chang YF, et al. Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: a systematic literature review and meta-analysis. Bone. 2018;111:92-100. 63.Wu CH, Kao IJ, Hung WC, et al. Economic impact and cost-effectiveness of fracture liaison services: a systematic review of the literature. Osteoporos Int. 2018;29(6):1227-42. 64.Delbar A, Pflimlin A, Delabrière I, et al. Persistence with osteoporosis treatment in patients from the Lille University Hospital Fracture Liaison Service. Bone. 2021;144:115838. 65.Park JH, Park EK, Koo DW, et al. Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis. BMC Musculoskelet Disord. 2017;18(1):152.
|